William Blair analyst Sami Corwin has maintained their neutral stance on BMRN stock, giving a Hold rating on May 2.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Sami Corwin’s rating is based on a combination of factors influencing BioMarin Pharmaceutical’s current and future prospects. The acquisition of Inozyme Pharma is seen as a positive step that could expand BioMarin’s market reach, particularly with the potential approval of larger indications for Voxzogo by 2030/2031. However, there are concerns about the company’s ability to significantly increase the patient base beyond the 670 patients already identified by Inozyme, which necessitates further patient-finding efforts.
Additionally, the potential impact of navepegritide on Voxzogo’s market share poses a short-term challenge, as Ascendis has submitted regulatory applications that could affect BioMarin’s commercial landscape. Despite these challenges, the company remains optimistic about future business development activities and has maintained its financial guidance for 2025 and 2026. These factors collectively contribute to the Hold rating, reflecting a balanced view of potential opportunities and risks.
In another report released on May 2, Scotiabank also maintained a Hold rating on the stock with a $80.00 price target.
Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BMRN in relation to earlier this year.